| Oct 9 |
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Oct 8 |
Morgan Stanley's Strategic Reduction in Replimune Group Inc Holdings
|
| Oct 2 |
Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 48% Below Their Intrinsic Value Estimate
|
| Sep 15 |
Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024
|
| Sep 9 |
Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024
|
| Sep 5 |
Stockholders Vote to Elect Madhavan Balachandran to Board of Directors
|
| Sep 3 |
Replimune: Strong Data In A Highly Differentiated Space
|
| Aug 22 |
Replimune Announces Late-Breaking Abstract of IGNYTE Clinical Trial Primary Analysis Selected for Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2024
|
| Aug 14 |
Replimune kickstarts Phase III melanoma trial studying RP1 immunotherapy
|
| Aug 13 |
Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma
|
